Beyond Air (XAIR) to Announce Earnings on Monday

Beyond Air (NASDAQ:XAIR) is expected to be releasing its Q4 2026 results before the market opens on Monday, June 29th. Analysts expect the company to post earnings of ($0.5667) per share and revenue of $2.2960 million for the quarter. Parties may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Thursday, July 2, 2026 at 4:00 PM ET.

Beyond Air Price Performance

Shares of NASDAQ:XAIR opened at $0.36 on Monday. Beyond Air has a fifty-two week low of $0.33 and a fifty-two week high of $5.70. The company has a quick ratio of 4.77, a current ratio of 5.12 and a debt-to-equity ratio of 2.65. The firm’s 50-day simple moving average is $0.48 and its 200-day simple moving average is $0.83. The company has a market cap of $4.75 million, a price-to-earnings ratio of -0.07 and a beta of 0.27.

Institutional Trading of Beyond Air

A number of large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its position in Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after purchasing an additional 34,000 shares in the last quarter. Virtu Financial LLC acquired a new position in Beyond Air in the 3rd quarter valued at about $48,000. Geode Capital Management LLC raised its stake in Beyond Air by 57.5% in the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock valued at $49,000 after purchasing an additional 24,695 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Beyond Air in the 3rd quarter valued at about $1,753,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

Wall Street Analyst Weigh In

XAIR has been the subject of a number of recent analyst reports. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Beyond Air in a research report on Friday, March 27th. Wall Street Zen upgraded Beyond Air to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Beyond Air in a research note on Friday, April 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.